Enovis's Revenue in the fiscal year 2025 $ 2,247.26 millions
Enovis's Revenue in the fiscal year 2024 $ 2,106.76 millions
Enovis's Revenue in the fiscal year 2023 $ 1,706.78 millions
Enovis's Revenue in the fiscal year 2022 $ 1,563.10 millions
Enovis's Revenue in the fiscal year 2021 $ 3,854.30 millions
ENOV Revenue second quarter 2026 Y/Y Growth Comment
Enovis Corp reported Revenue growth of 3.39% year on year in the second quarter 2026, to $ 582.78 millions, this is lower than Enovis Corp's recent average Revenue growth of 3.82%.
Looking into second quarter 2026 results within Medical Equipment & Supplies industry 128 other companies have achieved higher Revenue growth. While Enovis Corp' s Revenue increase of 3.39% ranks overall at the positon no. 2426 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Enovis's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
398.54 %
9.54 %
-50.07 %
(Mar 30 2012)
ENOV's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Enovis Corp disclosed decrease in Revenue from the first quarter by -0.97% to $ 582.78 millions, from $ 588.49 millions achived in the previous reporting period.
Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.
Within Medical Equipment & Supplies industry 77 other companies have achieved higher Revenue quarter on quarter growth. While Enovis's Revenue growth quarter on quarter, overall rank is 1960.
In the II. Quarter 2026 Enovis Corp disclosed decrease in Revenue from the first quarter by -0.97% to $ 582.78 millions, from $ 588.49 millions achived in the previous reporting period.
Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.
Within Medical Equipment & Supplies industry 77 other companies have achieved higher Revenue quarter on quarter growth. While Enovis's Revenue growth quarter on quarter, overall rank is 1960.
Enovis's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jul 03 2026)
12 Months Ending (Apr 03 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Oct 03 2025)
12 Months Ending (Jul 04 2025)
Cumulative Revenue 12 Months Ending
$ 2,294.94
$ 2,275.85
$ 2,245.60
$ 2,230.81
$ 2,187.36
Y / Y Revenue Growth (TTM)
4.92 %
5.93 %
6.62 %
11.53 %
14.36 %
Year on Year Revenue Growth Overall
Ranking
# 1141
# 429
# 287
# 108
# 354
Seqeuential Revenue Change (TTM)
0.84 %
1.35 %
0.66 %
1.99 %
1.81 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2426
# 1990
# 1642
# 1699
# 1479
Cumulative Revenue growth Comment
Assuming the Enovis's fiscal year would have ended in Jul 03 2026, Enovis would have reprted above average annual Revenue improvement of 4.92% year on year, of $ 2,295 millions. This marks a slow-down of the companys growth trends and from the 5.93% growth in Apr 03 2026.
In the Healthcare sector 210 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 429 to 1141.
Assuming the Enovis's fiscal year would have ended in Jul 03 2026, Enovis would have reprted above average annual Revenue improvement of 4.92% year on year, of $ 2,295 millions. This marks a slow-down of the companys growth trends and from the 5.93% growth in Apr 03 2026.
In the Healthcare sector 210 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 429 to 1141.
About Enovis Revenue Growth Rates (ENOV), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
3.39%